Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 2, 1996, Pages 277-283

  Bartolini, L ^a   Casamenti, F ^a   Pepeu, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

aniracetam; nucleus basalis; object recognition; scopolamine; working memory

Indexed keywords

AMPHETAMINE; ANIRACETAM; CHOLINE ACETYLTRANSFERASE; NOOTROPIC AGENT; OXIRACETAM; QUISQUALIC ACID; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE;

AGED; AGING; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DISCRIMINATION LEARNING; ENZYME ACTIVITY; MAGNOCELLULAR NUCLEUS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECOGNITION; SUBCUTANEOUS DRUG ADMINISTRATION; WORKING MEMORY;

ANIMALIA;

EID: 0030046826     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02021-7     Document Type: Article

References (45)

1. Bartolini, L.; Risaliti, R.; Pepeu, G. Effect of scopolamine and nootropic drugs on rewarded alternation in a T-maze. Pharmacol. Biochem. Behav. 43:1161-1164; 1992.
2. Bignami, G.; Michalek, H. Cholinergic mechanisms and aversively motivated behaviors. In: Anisman, H.; Bignami, G., eds. Psychopharmacology of aversively motivated behavior. New York: Plenum Press; 1978:173-255.
3. Bradford, M. M. A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254; 1976.
4. Casamenti, F.; Scali, C.; Vannucchi, M. G.; Bartolini, L.; Pepeu, G. Long-term ethanol consumption by rats: Effect on acetylchoHne release in vivo, choline acetyltransferase activity, and behavior. Neuroscience 56:465-471; 1993.
5. Cavoy, A.; Delacour, J. Spatial but not object recognition is impaired by aging rats. Physiol. Behav. 53:527-530; 1993.
6. Claus, J. J.; Ludwig, C.; Mohr, E.; Giuffra, M.; Blin, J.; Chase, T. N. Nootropic drugs in Alzheimer's disease: Symptomatic treatment with pramiracetam. Neurology 41:570-574; 1991.
7. Collerton, D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19:1-28; 1986.
8. Copani, A.; Genazzani, A.; Aleppo, G.; Casabona, G.; Canonico, P. L.; Scapagnini, U.; Nicoletti, F. Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. J. Neurochem. 58:1199-1204; 1992.
9. Cumin, R.; Bandle, E. F.; Gamzu, E.; Haefely, W. E. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berlin) 78:104-111; 1982.
10. Dunnett, S. B.; Evenden, J. L.; Iversen, S. D. Delay-dependent short-term memory deficits in aged rats. Psychopharmacology (Berlin) 96:174-189; 1988.
11. Dunnett, S. B.; Everitt, B. J.; Robbins, T. W. The basal forebrain Cholinergic system: Interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 14:494-501; 1991.
12. Dunnett, S. B.; Whishaw, I. Q.; Jones, G. H.; Bunch, S. T. Behavioural, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats. Neuroscience 20:653-669; 1987.
13. Ennaceur, A.; Cavoy, A.; Costa, J. C.; Delacour, J. A new one-trial test for neurobiological studies of memory in rats. II: Effects of piracetam and pramiracetam. Behav. Brain Res. 33:197-207; 1989.
14. Ennaceur, A.; Delacour, J. A new one trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31:47-59; 1988.
15. Fibiger, H. C. Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence. Trends Neurosci. 14:220-223; 1991.
16. Flicker, C.; Ferris, S. H.; Crrok, T.; Bartus, R. T.; Reisberg, B. Cognitive function in normal aging and early dementia. In: Traber, J.; Gispen, W. H., eds. Senile dementia of the Alzheimer Type. Berlin: Springer; 1985:2-17.
17. Fonnum, F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:407-409; 1975.
18. Gallagher, M.; Pelleymounter, M. Spatial learning deficits in old rats: A model for memory decline in aged. Neurobiol. Aging 9: 549-556; 1988.
19. Giovannini, M. G.; Rodinò, P.; Mutolo, D.; Pepeu, G. Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Dev. Res. 28:503-509; 1993.
20. Giurgea, C.; Salama, M. Nootropic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 1:235-247; 1977.
21. Gottfries, C. G. Alzheimer's disease and senile dementia: Biochemical characteristics and aspect of treatment. Psychopharmacology (Berlin) 86:245-252; 1985.
22. Green, R. C.; Goldstein, F. C.; Auchus, A. P.; Presley, R.; Clark, S.; VanTuyl, L.; Green, J.; Hesch, S. M.; Karp, H. R. Treatment trial of oxiracetam in Alzheimer's disease. Arch. Neurol. 49:1135-1136; 1992.
23. Ingram, D. K. Analysis of Age-related impairment in learning and memory in rodent models. In: Olton, D. S.; Gamzu, E.; Corkin, S., eds. Memory dysfunctions: An integration of animal and human research from preclinical and clinical perspectives, vol. 444. New York: New York Academy of Sciences; 1985:312-331.
24. Ito, I.; Tanabe, S.; Kohda, A.; Sugiyama, H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J. Physiol. 424:533-543; 1990.
25. Lee, C. R.; Benfield, P. Aniracetam: An overview of its pharmacodynamic and pharmacokinetic properties and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging 3: 257-273; 1994.
26. Lindner, M.; Balch, A. H.; VanderMaelen, C. P. Short forms of the "reference-" and "working-memory" Morris water maze for assessing age-related deficits. Behav. Neural Biol. 58:94-102; 1992.
27. LoConte, G.; Casamenti, F.; Bigl, V.; Milaneschi, E.; Pepeu, G. Effect of magnocellular forebrain lesions on acetylcholine output from the cerebral cortex, electrocorticogram and behaviour. Arch. Ital. Biol. 120:176-188; 1982.
28. Magnani, M.; Pozzi, O.; Biagetti, R.; Banfi, S.; Dorigotti, L. Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze. Psychopharmacology (Berlin) 106: 175-178; 1992.
29. Martinez, J. L.; Kesner, R. P., eds. Learning and memory. A biological view. 2nd ed. New York: Academic Press; 1991:563 p.
30. Mondadori, C. The pharmacology of the nootropics; New insights and new questions. Behav. Brain Res. 59:1-9; 1993.
31. Mulas, A.; Crabai, F.; Pepeu, G. The influence of repeated experience on the effect of scopolamine and of amphetamine on exploratory behaviour in the rat. Pharmacol. Res. Commun. 2:169-176; 1970.
32. Paxinos, G.; Watson, G., eds. The rat brain in stereotaxic coordinates. New York: Academic Press; 1982.
33. Pearce, J. M. An introduction to animal cognition. Howe: Lawrence Erlbaum Associates; 1987:328 p.
34. Pepeu, G.; Giovannelli, L. The central cholinergic system during aging. In: Bloom, F. E., ed. Neuroscience: From the molecular to the cognitive. Progress in Brain Research, vol. 100. Amsterdam: Elsevier; 1994:67-71.
35. Pepeu, G.; Spignoli, G. Nootropic drugs and brain cholinergic mechanisms. Prog. Neuropsychopharmacol, Biol. Psychiatry 13: S77-S88; 1989.
36. Pontecorvo, M. J.; Evans, H. L. Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacot. Biochem. Behav. 22:745-752; 1985.
37. Pugliese, A. M.; Corradetti, R.; Ballerini, L.; Pepeu, G. Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices. Br. J. Pharmacol. 99:189-193; 1990.
38. Sarter, M.; Hagan, J.; Dudchenko, P. Behavioral screening for cognition enhancers: From indiscriminate to valid testing: Part I. Psychopharmacology (Berlin) 107:144-159; 1992.
39. Sarter, M.; Hagan, J.; Dudchenko, P. Behavioral screening for cognition enhances: From indiscriminate to valid testing: Part II. Psychopharmacology (Berlin) 107:461-473; 1992.
40. Scali, C.; Casamenti, F.; Pazzagli, M.; Bartolini, L.; Pepeu, G. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci. Lett. 170:117-120; 1994.
41. Schindler, U. Preclinical evaluation of cognition enhancing drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 13:S99-S115; 1989.
42. Spignoli, G.; Pepeu, G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol. Biochem. Behav. 27:491-495; 1987.
43. Vannucchi, M. G.; Casamenti, F.; Pepeu, G. Decrease of acetylcholine release from cortical slices in aged rats: Investigations into its reversal by phosphatidylserine. J. Neurochem. 55:819-825; 1990.
44. Vernon, M. W.; Sorkin, E. M. Piracetam: An overview of its pharmacological properties, and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1:17-35; 1991.
45. Willig, F.; Palacios, A.; Monmaur, P.; M'Harzi, M.; Delacour, J. Short term memory, exploration and locomotor activity in aged rats. Neurobiol. Aging 8:393-402; 1987.